• Multiplexing With Ease

    PlexBio’s commitment to cancer discovery and treatment begins with early detection and the identification of precision treatments. Our proprietary cutting-edge multiplexing platform uses patented Precision Image Code  (PiCode) MicroDisc technology to provide rapid, cost-effective, streamline cancer diagnostics.

    中文版 ⟶

PlexBio’s Precision Image Code (πCode) MicroDiscs are circular, magnetic discs that are able to generate over 16,000 distinct image patterns for multiplexing applications. Virtually any probe used in molecular diagnostics can be conjugated to πCode MicroDiscs, including DNA, RNA, antigens, antibodies, proteins or chemical compounds.

πCode Technology

Liquid Biopsy 

The liquid biopsy approach, which uses blood and other bodily fluids that are more easily obtained, has the benefit of being non-invasive and less expensive than the traditional biopsy approach where samples are removed from the patient surgically or by needle aspiration.

Select Amp 


PlexBio has created multiplex allele specific PCR panels that can specifically detect DNA and RNA mutations, amplifications and translocations useful for clinical guideline-based therapeutic selection. The use of SelectAmp technology enables selective amplification of mutant DNA to enhance detection sensitivity.

Our Products



         PlexBio received CE Mark for the        
​    IntelliplexTM SARS-CoV-2 Detection kit

Denka Deepens  the Strategic Partnership with PlexBio Through Acquiring Over One-third of Its Stake

Sep 23, 2019

PlexBio Makes the List of 2019 Deloitte Asia Pacific Technology Fast 500

PlexBio announced that it ranked Number 217 on the Deloitte Technology Fast 500 Asia Pacific 2019.
Rankings are based on percentage revenue growth over there years.
PleBio grew 373% during this period.

                                      Read more

Jan 30, 2020